Business Wire

AtriCure Announces Launch of cryoSPHERE MAX™ Probe for Post-Operative Pain Management

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and ...
Business Wire

AtriCure Announces First Use of the AtriClip PRO-Mini ® Device

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and ...
Becker's ASC

Device Maker AtriCure to Pay $3.76M to Resolve Medicare Fraud Allegations

Medical device manufacturer AtriCure has agreed to pay $3.76 million to resolve civil Medicare fraud allegations that it marketed its medical devices to treat atrial fibrillation, a use not approved ...
Nasdaq

AtriCure Announces the Launch of the cryoXT™ Device for Post-Operative Pain Management Following Amputation

MASON, Ohio--(BUSINESS WIRE)-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and ...
MedCity News

AtriCure could pay $2.8M to settle claims it mis-marketed devices

AtriCure Inc. (NASDAQ: ATRC) has agreed to pay $2.8 million to settle a class-action shareholder lawsuit that stems from claims it promoted its surgical cardiac ablation devices for unapproved uses.
Nasdaq

AtriCure Announces First Use of the AtriClip PRO-Mini® Device

MASON, Ohio--(BUSINESS WIRE)-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and ...